Tetanus Toxoid Vaccine Market Size Estimation, Growth Rate, Industry Analysis, Global Forecast To 2019 - 2026

The rise in the number of reported cases of tetanus and diphtheria in the developing countries will be the major factor influencing the market growth.

Market Size – USD 4.35 Billion in 2018, Market Growth - CAGR of 4.9%, Market Trends – Low costs of vaccines.

The global tetanus toxoid vaccine market is expected to reach USD 6.46 Billion by 2026, according to a new report by Reports and Data. This can mainly be contributed by the rise in number of reported cases of tetanus and diphtheria in the developing countries. The low costs of the vaccine, as well as the increasing government initiatives towards technological improvements regarding immunization and vaccination, are also fuelling the growth of the market.

Several vaccine combinations include the tetanus vaccine such as Diphtheria, Tetanus, and Pertussis (DTaP); Monovalent Tetanus Toxoid (TT); Tetanus, Diphtheria, And Pertussis (Tdap); Diphtheria and Tetanus (DT); and others. DTaP and DT are used as a pediatric vaccine for children less than seven years old while Tdap and Td are given to those who are seven years old and above, where the lowercase, ‘d’ and ‘p’ denote the lower strengths of diphtheria and pertussis vaccines.

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/press-release/global-tetanus-toxoid-vaccine-market 

Further key findings from the report suggest

• The market is segmented on the basis of vaccine type into Diphtheria, Tetanus, and Pertussis (DTaP); Monovalent Tetanus Toxoid (TT); Tetanus, Diphtheria, And Pertussis (Tdap); Diphtheria and Tetanus (DT); and others. DTaP vaccines occupy the highest market share in the year 2018 and are forecasted to maintain its dominance throughout the forecast period, with a CAGR of 5.3%, owing to several initiatives and investments by governments to eradicate these diseases.
• Key participants include Merck & Co. Inc., GlaxoSmithKline Plc., Sanofi Pasteur, Inc., Pfizer, Inc., Bharat Biotech, AstraZeneca Plc., Valeant Pharmaceuticals, Shenzhen Kangtai Biological Products, Astellas Pharma Inc., Emergent Biosolutions Inc., and Panacea Biotec, among others.
• The companies have adopted various strategies including mergers, acquisitions, and partnerships to hold ongoing trails and come up with new developments in the market.

For the purpose of this report, Reports and Data have segmented global tetanus toxoid vaccine market on the basis of vaccine type, dosage, age group, end user, and region:

Vaccine type Outlook (Volume, Kilo tons; 2018-2026 and Revenue, USD Billion; 2018-2026)

• Monovalent Tetanus Toxoid (TT)
• Diphtheria, Tetanus, and Pertussis (DTaP)
• Diphtheria and Tetanus (DT)
• Tetanus, Diphtheria, And Pertussis (Tdap)
• Others

Dosage Outlook (Volume, Kilo tons; 2018-2026 And Revenue, USD Billion; 2018-2026)

• Quadrivalent
• Pentavalent
• Hexavalent

Age group Outlook (Volume, Kilo tons; 2018-2026 And Revenue, USD Billion; 2018-2026)

• Paediatric Vaccines
• Adult Vaccines

End users Outlook (Volume, Kilo tons; 2018-2026 And Revenue, USD Billion; 2018-2026)

• Hospitals And Clinics
• Government Organizations
• Research
• Others

Request For Free PDF Sample Of This Research Report At: https://www.reportsanddata.com/sample-enquiry-form/1287 

Regional Outlook (Volume, Kilo tons; 2018-2026 and Revenue, USD Billion; 2018-2026)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of APAC
• Latin America
  • Brazil
• MEA